Close Menu

NEW YORK (GenomeWeb) – The Japanese Ministry of Health, Labor, and Welfare has granted manufacturing and marketing approval for Myriad Genetics' BRACAnalysis Diagnostic System.

The test is approved as a companion diagnostic that can determine which metastatic, inoperable, or recurrent breast cancer patients have BRCA1 and BRCA2 genetic mutations, and therefore will likely to respond to the PARP inhibitor Lynparza (olaparib). Myriad will partner with Miraca Group subsidiary SRL, a large laboratory services provider in Japan, to commercialize BRACAnalysis in the country.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.